SG-3-06686 binds to CXCR3 receptor on dendritic cells, amplifies the natural ligand which induces a robust immune cell migration to the tumor microenvironment, ultimately resulting in tumor shrinkage.
Microbiome comparison between anti-PD-1 nonresponders and responders
enriched in anti-PD-1
SG-3-6686 peptide binds to CXCR3 receptor on dendritic cells
Amplifies natural ligand inducing robust immune cell migration to tumor microenvironment
Tumor shrinkage with single agent and in combination with anti-PD-1 in vivo
Tumor shrinkage in non-responders
SG-3-06686 targets recruitment of immune cells
External data and Second Genome internal data demonstrate CXCR3 chemokine system plays a key role in cancer
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy
Melvyn T. Chow et al.
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer.
Tino Vollmer et al.